Mature Dendritic Cell Production Using Closed Monocyte Enrichment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for producing mature dendritic cells from peripheral blood mononuclear cells (PBMCs) face challenges in scalability and contamination, making them unsuitable for large-scale production under Good Manufacturing Practices (cGMP) due to processes like plastic adherence and counterflow centrifugal elutriation.

Innovation Solution

A method involving the treatment of PBMCs with interleukin 4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to produce immature dendritic cells, followed by treatment with IL-4, GM-CSF, tumor necrosis factor alpha (TNF-α), and Prostaglandin E2 (PGE2) to generate mature dendritic cells, using cryopreserved peripheral blood stem cells (PBSCs) as a source when necessary.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If plastic adherence or counterflow centrifugal elutriation is used for monocyte enrichment, then monocyte separation can be achieved, but contamination risk increases and scalability is limited

Engineering Contradiction:

Improvemonocyte separation efficiencyVSAvoidcontamination risk

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent replaces mechanical separation methods (plastic adherence, counterflow centrifugal elutriation) with magnetic field-based separation using magnetic beads conjugated to monocytic markers. This substitution eliminates the contamination risks associated with open mechanical processes while maintaining effective monocyte enrichment, enabling cGMP-compliant large-scale production.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Quantity of substance

If traditional monocyte enrichment methods are used, then monocyte isolation is possible, but the process is not suitable for large-scale production under cGMP

Engineering Contradiction:

Improvemonocyte isolation capabilityVSAvoidlarge-scale production suitability

Core Design Contradiction:

Quantity of substanceVSProductivity

Solution Approach 1:

The patent replaces open mechanical separation processes with closed magnetic bead-based immunomagnetic separation. This enables scalable, cGMP-compliant production by eliminating contamination risks in open processes while maintaining effective monocyte isolation capability.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the separation parameter from mechanical properties (adherence, centrifugal force) to magnetic properties (magnetic bead conjugation to monocytic markers). This parameter change enables automated, closed-system processing suitable for large-scale cGMP production while maintaining isolation effectiveness.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If two-step cytokine treatment is used, then mature dendritic cell production is improved, but production time increases

Engineering Contradiction:

Improvemature dendritic cell qualityVSAvoidproduction cycle duration

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent performs preliminary monocyte enrichment and initial differentiation in a first step, then completes maturation in a second step. This staged approach ensures high-quality mature dendritic cells while optimizing total production time by performing essential preparatory actions before final maturation.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method enables efficient and high-yield production of mature dendritic cells, meeting cGMP standards by reducing contamination risks and enhancing productivity.

Implementation Method 1

treating the PBMCs with a cultivating medium supplemented with interleukin 4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to produce immature dendritic cells

Methodology Applied

Scientific EffectCytokine signaling:

Implementation Method 2

treating the immature dendritic cells of step (a) with the cultivating medium supplemented with IL-4, GM-CSF, tumor necrosis factor alpha (TNF-α), and Prostaglandin E2 (PGE2) to produce the mature dendritic cells

Methodology Applied

Scientific EffectCytokine signaling:

Implementation Method 3

subjecting the produced PBSCs stock of step (i) to a freezing treatment in a chamber, in which the ambient temperature of the chamber is decreased from about 4° C. to about −95° C. within about 55 to 70 minutes

Methodology Applied

Scientific EffectFreezing: Freezing

Data Source

PatentUS20250368957A1Method for producing mature dendritic cells

Publication Date: 2025.12.04 LIHPAO LIFE SCI CORP

AI summary

Disclosed herein is a method for producing mature dendritic cells from peripheral blood mononuclear cells (PBMCs). The method includes the steps of, treating the PBMCs with a cultivating medium supplemented with interleukin 4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to produce immature dendritic cells; and then treating the immature dendritic cells with the cultivating medium supplemented with IL-4, GM-CSF, tumor necrosis factor alpha (TNF-α), and Prostaglandin E2 (PGE2) to produce the mature dendritic cells. According to embodiments of the present disclosure, the PBMCs used in the present method are isolated from a leukocyte concentrate or a cryopreserved peripheral blood stem cells (PBSCs) stock.